Tenax Therapeutics, Inc. (NASDAQ:TENX – Get Rating) shares passed above its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $0.41 and traded as high as $2.28. Tenax Therapeutics shares last traded at $2.15, with a volume of 256,223 shares.
Wall Street Analyst Weigh In
Separately, StockNews.com started coverage on shares of Tenax Therapeutics in a research report on Sunday, January 8th. They issued a “sell” rating for the company.
Tenax Therapeutics Price Performance
The company’s 50-day moving average price is $0.77 and its two-hundred day moving average price is $0.41.
Institutional Investors Weigh In On Tenax Therapeutics
A hedge fund recently raised its stake in Tenax Therapeutics stock. Armistice Capital LLC lifted its holdings in shares of Tenax Therapeutics, Inc. (NASDAQ:TENX – Get Rating) by 23.1% in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 1,965,885 shares of the specialty pharmaceutical company’s stock after buying an additional 368,836 shares during the period. Armistice Capital LLC owned 7.80% of Tenax Therapeutics worth $334,000 at the end of the most recent reporting period. 34.08% of the stock is currently owned by hedge funds and other institutional investors.
About Tenax Therapeutics
Tenax Therapeutics, Inc, a specialty pharmaceutical company, engages in identifying, developing, and commercializing products for cardiovascular and pulmonary diseases in the United States and Canada. It develops TNX-103 and TNX-102 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of pulmonary arterial hypertension.
- Get a free copy of the StockNews.com research report on Tenax Therapeutics (TENX)
- Is It Time To Get Aggressive With Defense Stocks?
- 3 Retail Stocks Ringing the Register in 2023
- When Will Crane Holdings Take Flight?
- Qualcomm Gets a Boost from Analysts, but is it Time to Buy?
- EVgo Stock is Charged Up to Ride the EV Adoption Wave
Receive News & Ratings for Tenax Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tenax Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.